nodes	percent_of_prediction	percent_of_DWPC	metapath
Metipranolol—Atenolol—Procarbazine—hematologic cancer	0.677	1	CrCrCtD
Metipranolol—Acebutolol—SLC22A1—hematologic cancer	0.000862	0.506	CrCbGaD
Metipranolol—Atenolol—ABCB1—hematologic cancer	0.000272	0.16	CrCbGaD
Metipranolol—Acebutolol—ABCB1—hematologic cancer	0.000251	0.147	CrCbGaD
Metipranolol—Metoprolol—ABCB1—hematologic cancer	0.000212	0.124	CrCbGaD
Metipranolol—Nausea—Cladribine—hematologic cancer	0.000203	0.000705	CcSEcCtD
Metipranolol—Hypersensitivity—Vinorelbine—hematologic cancer	0.0002	0.000697	CcSEcCtD
Metipranolol—Dizziness—Lenalidomide—hematologic cancer	0.0002	0.000696	CcSEcCtD
Metipranolol—Dyspnoea—Irinotecan—hematologic cancer	0.0002	0.000695	CcSEcCtD
Metipranolol—Dyspnoea—Mitoxantrone—hematologic cancer	0.0002	0.000695	CcSEcCtD
Metipranolol—Asthenia—Bortezomib—hematologic cancer	0.0002	0.000695	CcSEcCtD
Metipranolol—Cough—Etoposide—hematologic cancer	0.000199	0.000694	CcSEcCtD
Metipranolol—Somnolence—Mitoxantrone—hematologic cancer	0.000199	0.000693	CcSEcCtD
Metipranolol—Somnolence—Irinotecan—hematologic cancer	0.000199	0.000693	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Gemcitabine—hematologic cancer	0.000199	0.000692	CcSEcCtD
Metipranolol—Asthenia—Bleomycin—hematologic cancer	0.000198	0.000689	CcSEcCtD
Metipranolol—Hypertension—Etoposide—hematologic cancer	0.000197	0.000686	CcSEcCtD
Metipranolol—Dizziness—Hydroxyurea—hematologic cancer	0.000197	0.000686	CcSEcCtD
Metipranolol—Rash—Melphalan—hematologic cancer	0.000196	0.000682	CcSEcCtD
Metipranolol—Dermatitis—Melphalan—hematologic cancer	0.000196	0.000682	CcSEcCtD
Metipranolol—Asthenia—Vinorelbine—hematologic cancer	0.000195	0.000678	CcSEcCtD
Metipranolol—Dyspnoea—Gemcitabine—hematologic cancer	0.000195	0.000677	CcSEcCtD
Metipranolol—Hypertension—Prednisolone—hematologic cancer	0.000195	0.000677	CcSEcCtD
Metipranolol—Nausea—Vinblastine—hematologic cancer	0.000194	0.000676	CcSEcCtD
Metipranolol—Somnolence—Gemcitabine—hematologic cancer	0.000194	0.000675	CcSEcCtD
Metipranolol—Discomfort—Etoposide—hematologic cancer	0.000192	0.000669	CcSEcCtD
Metipranolol—Bradycardia—Prednisone—hematologic cancer	0.000192	0.000666	CcSEcCtD
Metipranolol—Hypersensitivity—Thiotepa—hematologic cancer	0.000191	0.000665	CcSEcCtD
Metipranolol—Rash—Lenalidomide—hematologic cancer	0.000191	0.000664	CcSEcCtD
Metipranolol—Dermatitis—Lenalidomide—hematologic cancer	0.000191	0.000663	CcSEcCtD
Metipranolol—Discomfort—Prednisolone—hematologic cancer	0.00019	0.000659	CcSEcCtD
Metipranolol—Headache—Lenalidomide—hematologic cancer	0.00019	0.000659	CcSEcCtD
Metipranolol—Rash—Hydroxyurea—hematologic cancer	0.000188	0.000654	CcSEcCtD
Metipranolol—Dermatitis—Hydroxyurea—hematologic cancer	0.000188	0.000654	CcSEcCtD
Metipranolol—Headache—Hydroxyurea—hematologic cancer	0.000187	0.00065	CcSEcCtD
Metipranolol—Asthenia—Thiotepa—hematologic cancer	0.000186	0.000648	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Cisplatin—hematologic cancer	0.000186	0.000645	CcSEcCtD
Metipranolol—Hypersensitivity—Thalidomide—hematologic cancer	0.000185	0.000644	CcSEcCtD
Metipranolol—Nausea—Melphalan—hematologic cancer	0.000185	0.000643	CcSEcCtD
Metipranolol—Dizziness—Bortezomib—hematologic cancer	0.000184	0.00064	CcSEcCtD
Metipranolol—Oedema—Prednisolone—hematologic cancer	0.000184	0.00064	CcSEcCtD
Metipranolol—Dyspnoea—Cisplatin—hematologic cancer	0.000182	0.000631	CcSEcCtD
Metipranolol—Cough—Triamcinolone—hematologic cancer	0.000181	0.000629	CcSEcCtD
Metipranolol—Asthenia—Thalidomide—hematologic cancer	0.00018	0.000627	CcSEcCtD
Metipranolol—Dizziness—Vinorelbine—hematologic cancer	0.00018	0.000625	CcSEcCtD
Metipranolol—Nausea—Lenalidomide—hematologic cancer	0.00018	0.000625	CcSEcCtD
Metipranolol—Angina pectoris—Epirubicin—hematologic cancer	0.000179	0.000623	CcSEcCtD
Metipranolol—Hypertension—Triamcinolone—hematologic cancer	0.000179	0.000622	CcSEcCtD
Metipranolol—Hypersensitivity—Carmustine—hematologic cancer	0.000178	0.000618	CcSEcCtD
Metipranolol—Nausea—Hydroxyurea—hematologic cancer	0.000177	0.000616	CcSEcCtD
Metipranolol—Bronchitis—Epirubicin—hematologic cancer	0.000177	0.000615	CcSEcCtD
Metipranolol—Myalgia—Triamcinolone—hematologic cancer	0.000177	0.000614	CcSEcCtD
Metipranolol—Hypersensitivity—Alitretinoin—hematologic cancer	0.000176	0.000612	CcSEcCtD
Metipranolol—Rash—Bortezomib—hematologic cancer	0.000176	0.000611	CcSEcCtD
Metipranolol—Dermatitis—Bortezomib—hematologic cancer	0.000175	0.00061	CcSEcCtD
Metipranolol—Headache—Bortezomib—hematologic cancer	0.000175	0.000607	CcSEcCtD
Metipranolol—Discomfort—Triamcinolone—hematologic cancer	0.000174	0.000606	CcSEcCtD
Metipranolol—Rash—Bleomycin—hematologic cancer	0.000174	0.000606	CcSEcCtD
Metipranolol—Dermatitis—Bleomycin—hematologic cancer	0.000174	0.000605	CcSEcCtD
Metipranolol—Hypersensitivity—Ifosfamide—hematologic cancer	0.000174	0.000605	CcSEcCtD
Metipranolol—Asthenia—Carmustine—hematologic cancer	0.000173	0.000602	CcSEcCtD
Metipranolol—Dizziness—Thiotepa—hematologic cancer	0.000172	0.000597	CcSEcCtD
Metipranolol—Asthenia—Alitretinoin—hematologic cancer	0.000171	0.000596	CcSEcCtD
Metipranolol—Rash—Vinorelbine—hematologic cancer	0.000171	0.000596	CcSEcCtD
Metipranolol—Dermatitis—Vinorelbine—hematologic cancer	0.000171	0.000596	CcSEcCtD
Metipranolol—Headache—Vinorelbine—hematologic cancer	0.00017	0.000592	CcSEcCtD
Metipranolol—Conjunctivitis—Methotrexate—hematologic cancer	0.00017	0.000592	CcSEcCtD
Metipranolol—Hypersensitivity—Vincristine—hematologic cancer	0.00017	0.00059	CcSEcCtD
Metipranolol—Asthenia—Ifosfamide—hematologic cancer	0.000169	0.000589	CcSEcCtD
Metipranolol—Oedema—Triamcinolone—hematologic cancer	0.000169	0.000588	CcSEcCtD
Metipranolol—Dyspnoea—Etoposide—hematologic cancer	0.000166	0.000578	CcSEcCtD
Metipranolol—Dizziness—Thalidomide—hematologic cancer	0.000166	0.000578	CcSEcCtD
Metipranolol—Somnolence—Etoposide—hematologic cancer	0.000166	0.000577	CcSEcCtD
Metipranolol—Angina pectoris—Doxorubicin—hematologic cancer	0.000166	0.000576	CcSEcCtD
Metipranolol—Nausea—Bortezomib—hematologic cancer	0.000165	0.000575	CcSEcCtD
Metipranolol—Epistaxis—Methotrexate—hematologic cancer	0.000165	0.000575	CcSEcCtD
Metipranolol—Hypersensitivity—Irinotecan—hematologic cancer	0.000165	0.000575	CcSEcCtD
Metipranolol—Hypersensitivity—Mitoxantrone—hematologic cancer	0.000165	0.000575	CcSEcCtD
Metipranolol—Asthenia—Vincristine—hematologic cancer	0.000165	0.000575	CcSEcCtD
Metipranolol—Nausea—Bleomycin—hematologic cancer	0.000164	0.000571	CcSEcCtD
Metipranolol—Rash—Thiotepa—hematologic cancer	0.000164	0.000569	CcSEcCtD
Metipranolol—Bronchitis—Doxorubicin—hematologic cancer	0.000164	0.000569	CcSEcCtD
Metipranolol—Dermatitis—Thiotepa—hematologic cancer	0.000164	0.000569	CcSEcCtD
Metipranolol—Headache—Thiotepa—hematologic cancer	0.000163	0.000566	CcSEcCtD
Metipranolol—Hypertension—Dexamethasone—hematologic cancer	0.000162	0.000565	CcSEcCtD
Metipranolol—Hypertension—Betamethasone—hematologic cancer	0.000162	0.000565	CcSEcCtD
Metipranolol—Nausea—Vinorelbine—hematologic cancer	0.000162	0.000562	CcSEcCtD
Metipranolol—Asthenia—Mitoxantrone—hematologic cancer	0.000161	0.00056	CcSEcCtD
Metipranolol—Asthenia—Irinotecan—hematologic cancer	0.000161	0.00056	CcSEcCtD
Metipranolol—Myalgia—Dexamethasone—hematologic cancer	0.00016	0.000557	CcSEcCtD
Metipranolol—Myalgia—Betamethasone—hematologic cancer	0.00016	0.000557	CcSEcCtD
Metipranolol—Anxiety—Dexamethasone—hematologic cancer	0.00016	0.000555	CcSEcCtD
Metipranolol—Anxiety—Betamethasone—hematologic cancer	0.00016	0.000555	CcSEcCtD
Metipranolol—Dizziness—Carmustine—hematologic cancer	0.00016	0.000555	CcSEcCtD
Metipranolol—Conjunctivitis—Epirubicin—hematologic cancer	0.000159	0.000554	CcSEcCtD
Metipranolol—Rash—Thalidomide—hematologic cancer	0.000158	0.000551	CcSEcCtD
Metipranolol—Discomfort—Betamethasone—hematologic cancer	0.000158	0.00055	CcSEcCtD
Metipranolol—Discomfort—Dexamethasone—hematologic cancer	0.000158	0.00055	CcSEcCtD
Metipranolol—Dermatitis—Thalidomide—hematologic cancer	0.000158	0.00055	CcSEcCtD
Metipranolol—Dizziness—Alitretinoin—hematologic cancer	0.000158	0.00055	CcSEcCtD
Metipranolol—Headache—Thalidomide—hematologic cancer	0.000157	0.000547	CcSEcCtD
Metipranolol—Asthenia—Gemcitabine—hematologic cancer	0.000157	0.000545	CcSEcCtD
Metipranolol—Dizziness—Ifosfamide—hematologic cancer	0.000156	0.000543	CcSEcCtD
Metipranolol—Epistaxis—Epirubicin—hematologic cancer	0.000155	0.000538	CcSEcCtD
Metipranolol—Vision blurred—Prednisone—hematologic cancer	0.000154	0.000537	CcSEcCtD
Metipranolol—Nausea—Thiotepa—hematologic cancer	0.000154	0.000536	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	0.000154	0.000536	CcSEcCtD
Metipranolol—Oedema—Betamethasone—hematologic cancer	0.000154	0.000534	CcSEcCtD
Metipranolol—Oedema—Dexamethasone—hematologic cancer	0.000154	0.000534	CcSEcCtD
Metipranolol—Dizziness—Vincristine—hematologic cancer	0.000152	0.00053	CcSEcCtD
Metipranolol—Rash—Carmustine—hematologic cancer	0.000152	0.000529	CcSEcCtD
Metipranolol—Dermatitis—Carmustine—hematologic cancer	0.000152	0.000528	CcSEcCtD
Metipranolol—Visual impairment—Methotrexate—hematologic cancer	0.000152	0.000527	CcSEcCtD
Metipranolol—Headache—Carmustine—hematologic cancer	0.000151	0.000526	CcSEcCtD
Metipranolol—Dyspnoea—Triamcinolone—hematologic cancer	0.000151	0.000525	CcSEcCtD
Metipranolol—Rash—Alitretinoin—hematologic cancer	0.000151	0.000524	CcSEcCtD
Metipranolol—Dermatitis—Alitretinoin—hematologic cancer	0.000151	0.000523	CcSEcCtD
Metipranolol—Hypersensitivity—Cisplatin—hematologic cancer	0.00015	0.000522	CcSEcCtD
Metipranolol—Bradycardia—Epirubicin—hematologic cancer	0.00015	0.000521	CcSEcCtD
Metipranolol—Headache—Alitretinoin—hematologic cancer	0.00015	0.000521	CcSEcCtD
Metipranolol—Nausea—Thalidomide—hematologic cancer	0.000149	0.000519	CcSEcCtD
Metipranolol—Rash—Ifosfamide—hematologic cancer	0.000149	0.000518	CcSEcCtD
Metipranolol—Dermatitis—Ifosfamide—hematologic cancer	0.000149	0.000517	CcSEcCtD
Metipranolol—Dizziness—Irinotecan—hematologic cancer	0.000148	0.000516	CcSEcCtD
Metipranolol—Rhinitis—Epirubicin—hematologic cancer	0.000148	0.000513	CcSEcCtD
Metipranolol—Conjunctivitis—Doxorubicin—hematologic cancer	0.000147	0.000513	CcSEcCtD
Metipranolol—Asthenia—Cisplatin—hematologic cancer	0.000146	0.000508	CcSEcCtD
Metipranolol—Rash—Vincristine—hematologic cancer	0.000145	0.000505	CcSEcCtD
Metipranolol—Dermatitis—Vincristine—hematologic cancer	0.000145	0.000504	CcSEcCtD
Metipranolol—Headache—Vincristine—hematologic cancer	0.000144	0.000502	CcSEcCtD
Metipranolol—Nausea—Carmustine—hematologic cancer	0.000143	0.000498	CcSEcCtD
Metipranolol—Epistaxis—Doxorubicin—hematologic cancer	0.000143	0.000498	CcSEcCtD
Metipranolol—Nausea—Alitretinoin—hematologic cancer	0.000142	0.000494	CcSEcCtD
Metipranolol—Visual impairment—Epirubicin—hematologic cancer	0.000142	0.000493	CcSEcCtD
Metipranolol—Hypertension—Prednisone—hematologic cancer	0.000141	0.000492	CcSEcCtD
Metipranolol—Rash—Irinotecan—hematologic cancer	0.000141	0.000492	CcSEcCtD
Metipranolol—Rash—Mitoxantrone—hematologic cancer	0.000141	0.000492	CcSEcCtD
Metipranolol—Dermatitis—Irinotecan—hematologic cancer	0.000141	0.000491	CcSEcCtD
Metipranolol—Dermatitis—Mitoxantrone—hematologic cancer	0.000141	0.000491	CcSEcCtD
Metipranolol—Headache—Irinotecan—hematologic cancer	0.000141	0.000489	CcSEcCtD
Metipranolol—Headache—Mitoxantrone—hematologic cancer	0.000141	0.000489	CcSEcCtD
Metipranolol—Nausea—Ifosfamide—hematologic cancer	0.00014	0.000488	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	0.00014	0.000486	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Betamethasone—hematologic cancer	0.00014	0.000486	CcSEcCtD
Metipranolol—Myalgia—Prednisone—hematologic cancer	0.000139	0.000485	CcSEcCtD
Metipranolol—Anxiety—Prednisone—hematologic cancer	0.000139	0.000483	CcSEcCtD
Metipranolol—Bradycardia—Doxorubicin—hematologic cancer	0.000139	0.000482	CcSEcCtD
Metipranolol—Discomfort—Prednisone—hematologic cancer	0.000138	0.000479	CcSEcCtD
Metipranolol—Rash—Gemcitabine—hematologic cancer	0.000138	0.000479	CcSEcCtD
Metipranolol—Dermatitis—Gemcitabine—hematologic cancer	0.000138	0.000479	CcSEcCtD
Metipranolol—Hypersensitivity—Etoposide—hematologic cancer	0.000137	0.000478	CcSEcCtD
Metipranolol—Headache—Gemcitabine—hematologic cancer	0.000137	0.000476	CcSEcCtD
Metipranolol—Nausea—Vincristine—hematologic cancer	0.000137	0.000476	CcSEcCtD
Metipranolol—Rhinitis—Doxorubicin—hematologic cancer	0.000137	0.000475	CcSEcCtD
Metipranolol—Hypersensitivity—Prednisolone—hematologic cancer	0.000136	0.000471	CcSEcCtD
Metipranolol—Asthenia—Etoposide—hematologic cancer	0.000134	0.000465	CcSEcCtD
Metipranolol—Oedema—Prednisone—hematologic cancer	0.000134	0.000465	CcSEcCtD
Metipranolol—Nausea—Irinotecan—hematologic cancer	0.000133	0.000463	CcSEcCtD
Metipranolol—Nausea—Mitoxantrone—hematologic cancer	0.000133	0.000463	CcSEcCtD
Metipranolol—Visual impairment—Doxorubicin—hematologic cancer	0.000131	0.000456	CcSEcCtD
Metipranolol—Nausea—Gemcitabine—hematologic cancer	0.00013	0.000451	CcSEcCtD
Metipranolol—Vision blurred—Methotrexate—hematologic cancer	0.000129	0.000449	CcSEcCtD
Metipranolol—Rash—Cisplatin—hematologic cancer	0.000128	0.000446	CcSEcCtD
Metipranolol—Dermatitis—Cisplatin—hematologic cancer	0.000128	0.000446	CcSEcCtD
Metipranolol—Tension—Epirubicin—hematologic cancer	0.000126	0.000437	CcSEcCtD
Metipranolol—Hypersensitivity—Triamcinolone—hematologic cancer	0.000125	0.000433	CcSEcCtD
Metipranolol—Nervousness—Epirubicin—hematologic cancer	0.000124	0.000433	CcSEcCtD
Metipranolol—Dizziness—Etoposide—hematologic cancer	0.000123	0.000429	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Prednisone—hematologic cancer	0.000122	0.000424	CcSEcCtD
Metipranolol—Dizziness—Prednisolone—hematologic cancer	0.000122	0.000423	CcSEcCtD
Metipranolol—Asthenia—Triamcinolone—hematologic cancer	0.000121	0.000422	CcSEcCtD
Metipranolol—Nausea—Cisplatin—hematologic cancer	0.000121	0.000421	CcSEcCtD
Metipranolol—Vision blurred—Epirubicin—hematologic cancer	0.000121	0.00042	CcSEcCtD
Metipranolol—Cough—Methotrexate—hematologic cancer	0.000119	0.000415	CcSEcCtD
Metipranolol—Rash—Etoposide—hematologic cancer	0.000118	0.000409	CcSEcCtD
Metipranolol—Dermatitis—Etoposide—hematologic cancer	0.000118	0.000409	CcSEcCtD
Metipranolol—Headache—Etoposide—hematologic cancer	0.000117	0.000406	CcSEcCtD
Metipranolol—Myalgia—Methotrexate—hematologic cancer	0.000117	0.000405	CcSEcCtD
Metipranolol—Tension—Doxorubicin—hematologic cancer	0.000116	0.000405	CcSEcCtD
Metipranolol—Rash—Prednisolone—hematologic cancer	0.000116	0.000403	CcSEcCtD
Metipranolol—Dermatitis—Prednisolone—hematologic cancer	0.000116	0.000403	CcSEcCtD
Metipranolol—Headache—Prednisolone—hematologic cancer	0.000115	0.000401	CcSEcCtD
Metipranolol—Discomfort—Methotrexate—hematologic cancer	0.000115	0.0004	CcSEcCtD
Metipranolol—Nervousness—Doxorubicin—hematologic cancer	0.000115	0.0004	CcSEcCtD
Metipranolol—Palpitations—Epirubicin—hematologic cancer	0.000113	0.000394	CcSEcCtD
Metipranolol—Dizziness—Triamcinolone—hematologic cancer	0.000112	0.000389	CcSEcCtD
Metipranolol—Cough—Epirubicin—hematologic cancer	0.000112	0.000389	CcSEcCtD
Metipranolol—Vision blurred—Doxorubicin—hematologic cancer	0.000112	0.000389	CcSEcCtD
Metipranolol—Nausea—Etoposide—hematologic cancer	0.000111	0.000385	CcSEcCtD
Metipranolol—Hypertension—Epirubicin—hematologic cancer	0.000111	0.000385	CcSEcCtD
Metipranolol—Asthenia—Dexamethasone—hematologic cancer	0.00011	0.000383	CcSEcCtD
Metipranolol—Asthenia—Betamethasone—hematologic cancer	0.00011	0.000383	CcSEcCtD
Metipranolol—Nausea—Prednisolone—hematologic cancer	0.000109	0.00038	CcSEcCtD
Metipranolol—Myalgia—Epirubicin—hematologic cancer	0.000109	0.000379	CcSEcCtD
Metipranolol—Anxiety—Epirubicin—hematologic cancer	0.000109	0.000378	CcSEcCtD
Metipranolol—Discomfort—Epirubicin—hematologic cancer	0.000108	0.000375	CcSEcCtD
Metipranolol—Propranolol—ABCB1—hematologic cancer	0.000107	0.0627	CrCbGaD
Metipranolol—Rash—Triamcinolone—hematologic cancer	0.000107	0.000371	CcSEcCtD
Metipranolol—Dermatitis—Triamcinolone—hematologic cancer	0.000107	0.000371	CcSEcCtD
Metipranolol—Headache—Triamcinolone—hematologic cancer	0.000106	0.000369	CcSEcCtD
Metipranolol—Palpitations—Doxorubicin—hematologic cancer	0.000105	0.000364	CcSEcCtD
Metipranolol—Oedema—Epirubicin—hematologic cancer	0.000105	0.000364	CcSEcCtD
Metipranolol—Cough—Doxorubicin—hematologic cancer	0.000103	0.00036	CcSEcCtD
Metipranolol—Hypertension—Doxorubicin—hematologic cancer	0.000102	0.000356	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Methotrexate—hematologic cancer	0.000102	0.000354	CcSEcCtD
Metipranolol—Dizziness—Betamethasone—hematologic cancer	0.000102	0.000353	CcSEcCtD
Metipranolol—Dizziness—Dexamethasone—hematologic cancer	0.000102	0.000353	CcSEcCtD
Metipranolol—Myalgia—Doxorubicin—hematologic cancer	0.000101	0.000351	CcSEcCtD
Metipranolol—Anxiety—Doxorubicin—hematologic cancer	0.000101	0.00035	CcSEcCtD
Metipranolol—Nausea—Triamcinolone—hematologic cancer	0.000101	0.000349	CcSEcCtD
Metipranolol—Discomfort—Doxorubicin—hematologic cancer	9.97e-05	0.000347	CcSEcCtD
Metipranolol—Dyspnoea—Methotrexate—hematologic cancer	9.96e-05	0.000346	CcSEcCtD
Metipranolol—Somnolence—Methotrexate—hematologic cancer	9.94e-05	0.000345	CcSEcCtD
Metipranolol—Hypersensitivity—Prednisone—hematologic cancer	9.85e-05	0.000343	CcSEcCtD
Metipranolol—Rash—Dexamethasone—hematologic cancer	9.68e-05	0.000337	CcSEcCtD
Metipranolol—Rash—Betamethasone—hematologic cancer	9.68e-05	0.000337	CcSEcCtD
Metipranolol—Oedema—Doxorubicin—hematologic cancer	9.68e-05	0.000336	CcSEcCtD
Metipranolol—Dermatitis—Dexamethasone—hematologic cancer	9.67e-05	0.000336	CcSEcCtD
Metipranolol—Dermatitis—Betamethasone—hematologic cancer	9.67e-05	0.000336	CcSEcCtD
Metipranolol—Headache—Dexamethasone—hematologic cancer	9.62e-05	0.000334	CcSEcCtD
Metipranolol—Headache—Betamethasone—hematologic cancer	9.62e-05	0.000334	CcSEcCtD
Metipranolol—Asthenia—Prednisone—hematologic cancer	9.59e-05	0.000334	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Epirubicin—hematologic cancer	9.53e-05	0.000331	CcSEcCtD
Metipranolol—Dyspnoea—Epirubicin—hematologic cancer	9.32e-05	0.000324	CcSEcCtD
Metipranolol—Somnolence—Epirubicin—hematologic cancer	9.3e-05	0.000323	CcSEcCtD
Metipranolol—Nausea—Dexamethasone—hematologic cancer	9.12e-05	0.000317	CcSEcCtD
Metipranolol—Nausea—Betamethasone—hematologic cancer	9.12e-05	0.000317	CcSEcCtD
Metipranolol—Dizziness—Prednisone—hematologic cancer	8.84e-05	0.000307	CcSEcCtD
Metipranolol—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	8.82e-05	0.000307	CcSEcCtD
Metipranolol—Dyspnoea—Doxorubicin—hematologic cancer	8.63e-05	0.0003	CcSEcCtD
Metipranolol—Somnolence—Doxorubicin—hematologic cancer	8.6e-05	0.000299	CcSEcCtD
Metipranolol—Rash—Prednisone—hematologic cancer	8.43e-05	0.000293	CcSEcCtD
Metipranolol—Dermatitis—Prednisone—hematologic cancer	8.42e-05	0.000293	CcSEcCtD
Metipranolol—Headache—Prednisone—hematologic cancer	8.38e-05	0.000291	CcSEcCtD
Metipranolol—Hypersensitivity—Methotrexate—hematologic cancer	8.23e-05	0.000286	CcSEcCtD
Metipranolol—Asthenia—Methotrexate—hematologic cancer	8.02e-05	0.000279	CcSEcCtD
Metipranolol—Nausea—Prednisone—hematologic cancer	7.94e-05	0.000276	CcSEcCtD
Metipranolol—Hypersensitivity—Epirubicin—hematologic cancer	7.71e-05	0.000268	CcSEcCtD
Metipranolol—Asthenia—Epirubicin—hematologic cancer	7.5e-05	0.000261	CcSEcCtD
Metipranolol—Dizziness—Methotrexate—hematologic cancer	7.39e-05	0.000257	CcSEcCtD
Metipranolol—Hypersensitivity—Doxorubicin—hematologic cancer	7.13e-05	0.000248	CcSEcCtD
Metipranolol—Rash—Methotrexate—hematologic cancer	7.05e-05	0.000245	CcSEcCtD
Metipranolol—Dermatitis—Methotrexate—hematologic cancer	7.04e-05	0.000245	CcSEcCtD
Metipranolol—Headache—Methotrexate—hematologic cancer	7e-05	0.000243	CcSEcCtD
Metipranolol—Asthenia—Doxorubicin—hematologic cancer	6.94e-05	0.000241	CcSEcCtD
Metipranolol—Dizziness—Epirubicin—hematologic cancer	6.92e-05	0.00024	CcSEcCtD
Metipranolol—Nausea—Methotrexate—hematologic cancer	6.64e-05	0.000231	CcSEcCtD
Metipranolol—Rash—Epirubicin—hematologic cancer	6.59e-05	0.000229	CcSEcCtD
Metipranolol—Dermatitis—Epirubicin—hematologic cancer	6.59e-05	0.000229	CcSEcCtD
Metipranolol—Headache—Epirubicin—hematologic cancer	6.55e-05	0.000228	CcSEcCtD
Metipranolol—Dizziness—Doxorubicin—hematologic cancer	6.4e-05	0.000222	CcSEcCtD
Metipranolol—Nausea—Epirubicin—hematologic cancer	6.21e-05	0.000216	CcSEcCtD
Metipranolol—Rash—Doxorubicin—hematologic cancer	6.1e-05	0.000212	CcSEcCtD
Metipranolol—Dermatitis—Doxorubicin—hematologic cancer	6.1e-05	0.000212	CcSEcCtD
Metipranolol—Headache—Doxorubicin—hematologic cancer	6.06e-05	0.000211	CcSEcCtD
Metipranolol—Nausea—Doxorubicin—hematologic cancer	5.75e-05	0.0002	CcSEcCtD
Metipranolol—ADRB1—Signaling Pathways—STAT5B—hematologic cancer	2.1e-05	0.00062	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—JAK1—hematologic cancer	2.09e-05	0.000617	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PRKCG—hematologic cancer	2.09e-05	0.000617	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—RAC2—hematologic cancer	2.08e-05	0.000616	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—DKK1—hematologic cancer	2.07e-05	0.000611	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—STAT5B—hematologic cancer	2.05e-05	0.000606	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ADCY7—hematologic cancer	2.03e-05	0.000602	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CSF2—hematologic cancer	2.01e-05	0.000594	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—IL2RA—hematologic cancer	1.99e-05	0.000589	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ADCY7—hematologic cancer	1.99e-05	0.000589	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—XIAP—hematologic cancer	1.98e-05	0.000585	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CSF2—hematologic cancer	1.96e-05	0.000581	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—IL2RA—hematologic cancer	1.95e-05	0.000577	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—JAK1—hematologic cancer	1.94e-05	0.000573	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PRKCG—hematologic cancer	1.94e-05	0.000573	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—XIAP—hematologic cancer	1.94e-05	0.000573	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SH2B3—hematologic cancer	1.93e-05	0.000571	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SMARCA4—hematologic cancer	1.93e-05	0.000571	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GZMB—hematologic cancer	1.92e-05	0.000567	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PRKCG—hematologic cancer	1.89e-05	0.000561	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—JAK1—hematologic cancer	1.89e-05	0.000561	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SMARCA4—hematologic cancer	1.89e-05	0.000558	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SH2B3—hematologic cancer	1.89e-05	0.000558	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GZMB—hematologic cancer	1.87e-05	0.000555	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CTNNA1—hematologic cancer	1.87e-05	0.000554	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EIF4EBP1—hematologic cancer	1.86e-05	0.00055	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HSPB1—hematologic cancer	1.86e-05	0.00055	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCL3—hematologic cancer	1.86e-05	0.00055	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SDC1—hematologic cancer	1.84e-05	0.000544	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PTHLH—hematologic cancer	1.84e-05	0.000544	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CTNNA1—hematologic cancer	1.83e-05	0.000542	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HSPB1—hematologic cancer	1.82e-05	0.000538	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EIF4EBP1—hematologic cancer	1.82e-05	0.000538	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCL3—hematologic cancer	1.82e-05	0.000538	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—IL2RA—hematologic cancer	1.81e-05	0.000535	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PTHLH—hematologic cancer	1.8e-05	0.000532	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SDC1—hematologic cancer	1.8e-05	0.000532	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PTGER4—hematologic cancer	1.79e-05	0.00053	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—LCK—hematologic cancer	1.78e-05	0.000527	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—IL2RA—hematologic cancer	1.77e-05	0.000524	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PTGER4—hematologic cancer	1.75e-05	0.000518	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—H3F3A—hematologic cancer	1.75e-05	0.000517	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—LCK—hematologic cancer	1.74e-05	0.000516	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—H3F3A—hematologic cancer	1.71e-05	0.000505	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PRKCZ—hematologic cancer	1.7e-05	0.000502	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PRKCZ—hematologic cancer	1.66e-05	0.000491	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CG—hematologic cancer	1.66e-05	0.000491	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PARP1—hematologic cancer	1.64e-05	0.000485	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CG—hematologic cancer	1.62e-05	0.00048	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FBXW7—hematologic cancer	1.61e-05	0.000477	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PARP1—hematologic cancer	1.6e-05	0.000475	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CXCR4—hematologic cancer	1.58e-05	0.000468	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HDAC2—hematologic cancer	1.58e-05	0.000468	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FBXW7—hematologic cancer	1.58e-05	0.000467	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HDAC2—hematologic cancer	1.55e-05	0.000458	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CXCR4—hematologic cancer	1.55e-05	0.000458	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CBL—hematologic cancer	1.54e-05	0.000456	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IL3—hematologic cancer	1.53e-05	0.000451	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CBL—hematologic cancer	1.51e-05	0.000446	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CG—hematologic cancer	1.51e-05	0.000446	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PTPN1—hematologic cancer	1.5e-05	0.000444	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IL3—hematologic cancer	1.49e-05	0.000441	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PTPN11—hematologic cancer	1.48e-05	0.000438	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—RASGRP1—hematologic cancer	1.48e-05	0.000437	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CG—hematologic cancer	1.47e-05	0.000436	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HSP90AA1—hematologic cancer	1.47e-05	0.000435	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SYK—hematologic cancer	1.47e-05	0.000435	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PTPN1—hematologic cancer	1.47e-05	0.000434	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CD—hematologic cancer	1.46e-05	0.000432	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PTPN11—hematologic cancer	1.45e-05	0.000428	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—RASGRP1—hematologic cancer	1.44e-05	0.000427	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SYK—hematologic cancer	1.44e-05	0.000426	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HSP90AA1—hematologic cancer	1.44e-05	0.000426	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CREB1—hematologic cancer	1.43e-05	0.000424	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CD—hematologic cancer	1.43e-05	0.000422	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—STAT1—hematologic cancer	1.42e-05	0.00042	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—CCL2—hematologic cancer	1.4e-05	0.000415	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CREB1—hematologic cancer	1.4e-05	0.000415	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—IL6R—hematologic cancer	1.4e-05	0.000414	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—STAT1—hematologic cancer	1.39e-05	0.00041	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3R1—hematologic cancer	1.38e-05	0.000408	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—CCL2—hematologic cancer	1.37e-05	0.000406	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—IL6R—hematologic cancer	1.37e-05	0.000405	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3R1—hematologic cancer	1.35e-05	0.000399	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—JAK2—hematologic cancer	1.34e-05	0.000396	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—MAP2K1—hematologic cancer	1.33e-05	0.000395	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—GRB2—hematologic cancer	1.33e-05	0.000393	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CD—hematologic cancer	1.32e-05	0.000392	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PDGFA—hematologic cancer	1.32e-05	0.000392	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—JAK2—hematologic cancer	1.31e-05	0.000387	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—KITLG—hematologic cancer	1.3e-05	0.000386	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—MAP2K1—hematologic cancer	1.3e-05	0.000386	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—GRB2—hematologic cancer	1.3e-05	0.000384	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CD—hematologic cancer	1.3e-05	0.000383	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PDGFA—hematologic cancer	1.29e-05	0.000383	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—KITLG—hematologic cancer	1.28e-05	0.000378	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—STAT5A—hematologic cancer	1.28e-05	0.000377	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CB—hematologic cancer	1.27e-05	0.000376	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CDKN2B—hematologic cancer	1.26e-05	0.000374	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3R1—hematologic cancer	1.25e-05	0.00037	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—STAT5A—hematologic cancer	1.25e-05	0.000369	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CB—hematologic cancer	1.24e-05	0.000368	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CDKN2B—hematologic cancer	1.24e-05	0.000366	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3R1—hematologic cancer	1.22e-05	0.000362	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CD86—hematologic cancer	1.22e-05	0.000362	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—JAK2—hematologic cancer	1.22e-05	0.00036	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HES1—hematologic cancer	1.21e-05	0.000357	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NCOR1—hematologic cancer	1.2e-05	0.000355	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CD86—hematologic cancer	1.2e-05	0.000354	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—JAK2—hematologic cancer	1.19e-05	0.000352	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CSF2—hematologic cancer	1.19e-05	0.000351	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FGF1—hematologic cancer	1.19e-05	0.000351	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HES1—hematologic cancer	1.18e-05	0.000349	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NCOR1—hematologic cancer	1.17e-05	0.000347	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FOXO1—hematologic cancer	1.17e-05	0.000346	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—IL2—hematologic cancer	1.17e-05	0.000346	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PDGFRB—hematologic cancer	1.17e-05	0.000345	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FGF1—hematologic cancer	1.16e-05	0.000343	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CSF2—hematologic cancer	1.16e-05	0.000343	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CB—hematologic cancer	1.15e-05	0.000342	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PDGFRA—hematologic cancer	1.15e-05	0.00034	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PRKCG—hematologic cancer	1.14e-05	0.000339	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—JAK1—hematologic cancer	1.14e-05	0.000339	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FOXO1—hematologic cancer	1.14e-05	0.000338	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—IL2—hematologic cancer	1.14e-05	0.000338	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PDGFRB—hematologic cancer	1.14e-05	0.000338	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CB—hematologic cancer	1.13e-05	0.000334	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PDGFRA—hematologic cancer	1.12e-05	0.000332	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PRKCG—hematologic cancer	1.12e-05	0.000331	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—JAK1—hematologic cancer	1.12e-05	0.000331	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IL2RA—hematologic cancer	1.07e-05	0.000316	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—IL2—hematologic cancer	1.06e-05	0.000314	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TERT—hematologic cancer	1.06e-05	0.000313	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IL2RA—hematologic cancer	1.05e-05	0.000309	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—IL2—hematologic cancer	1.04e-05	0.000307	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TERT—hematologic cancer	1.03e-05	0.000306	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PDGFB—hematologic cancer	1.03e-05	0.000305	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PDGFB—hematologic cancer	1.01e-05	0.000298	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TSC2—hematologic cancer	1.01e-05	0.000298	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TSC2—hematologic cancer	9.86e-06	0.000292	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FGFR3—hematologic cancer	9.7e-06	0.000287	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MAPK14—hematologic cancer	9.6e-06	0.000284	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FGFR3—hematologic cancer	9.48e-06	0.000281	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—ESR1—hematologic cancer	9.42e-06	0.000279	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MAPK14—hematologic cancer	9.39e-06	0.000278	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FN1—hematologic cancer	9.3e-06	0.000275	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—ESR1—hematologic cancer	9.21e-06	0.000273	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—BAD—hematologic cancer	9.19e-06	0.000272	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NFKBIA—hematologic cancer	9.19e-06	0.000272	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NOTCH1—hematologic cancer	9.1e-06	0.000269	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FN1—hematologic cancer	9.1e-06	0.000269	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NFKBIA—hematologic cancer	8.99e-06	0.000266	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—BAD—hematologic cancer	8.99e-06	0.000266	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CD80—hematologic cancer	8.92e-06	0.000264	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NOTCH1—hematologic cancer	8.9e-06	0.000263	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CG—hematologic cancer	8.9e-06	0.000263	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—KIT—hematologic cancer	8.9e-06	0.000263	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—NRAS—hematologic cancer	8.9e-06	0.000263	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PTPN11—hematologic cancer	8.75e-06	0.000259	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CD80—hematologic cancer	8.72e-06	0.000258	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CG—hematologic cancer	8.71e-06	0.000258	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—KIT—hematologic cancer	8.71e-06	0.000258	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—NRAS—hematologic cancer	8.71e-06	0.000258	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PTPN11—hematologic cancer	8.56e-06	0.000253	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—MAPK3—hematologic cancer	8.53e-06	0.000252	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CREB1—hematologic cancer	8.47e-06	0.000251	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—BRAF—hematologic cancer	8.37e-06	0.000248	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—MAPK3—hematologic cancer	8.34e-06	0.000247	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCL2—hematologic cancer	8.29e-06	0.000245	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CREB1—hematologic cancer	8.29e-06	0.000245	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IL6R—hematologic cancer	8.27e-06	0.000245	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CREBBP—hematologic cancer	8.25e-06	0.000244	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—BRAF—hematologic cancer	8.19e-06	0.000242	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCL2—hematologic cancer	8.11e-06	0.00024	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IL6R—hematologic cancer	8.09e-06	0.000239	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CREBBP—hematologic cancer	8.07e-06	0.000239	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MAP2K1—hematologic cancer	7.88e-06	0.000233	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CD—hematologic cancer	7.83e-06	0.000232	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—PIK3CA—hematologic cancer	7.75e-06	0.000229	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MAP2K1—hematologic cancer	7.71e-06	0.000228	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—KRAS—hematologic cancer	7.66e-06	0.000227	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CD—hematologic cancer	7.66e-06	0.000226	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—PIK3CA—hematologic cancer	7.58e-06	0.000224	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—KRAS—hematologic cancer	7.49e-06	0.000222	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—FGF2—hematologic cancer	7.49e-06	0.000222	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3R1—hematologic cancer	7.39e-06	0.000219	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—FGF2—hematologic cancer	7.33e-06	0.000217	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3R1—hematologic cancer	7.23e-06	0.000214	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—JAK2—hematologic cancer	7.18e-06	0.000212	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—PIK3CA—hematologic cancer	7.04e-06	0.000208	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—JAK2—hematologic cancer	7.03e-06	0.000208	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MDM2—hematologic cancer	7.01e-06	0.000207	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—PIK3CA—hematologic cancer	6.89e-06	0.000204	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MDM2—hematologic cancer	6.86e-06	0.000203	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MTOR—hematologic cancer	6.82e-06	0.000202	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CB—hematologic cancer	6.82e-06	0.000202	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CB—hematologic cancer	6.67e-06	0.000197	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MTOR—hematologic cancer	6.67e-06	0.000197	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—HRAS—hematologic cancer	6.51e-06	0.000193	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CDKN1B—hematologic cancer	6.4e-06	0.000189	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—HRAS—hematologic cancer	6.37e-06	0.000188	CbGpPWpGaD
Metipranolol—ADRB1—GPCR downstream signaling—AKT1—hematologic cancer	6.33e-06	0.000187	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CASP3—hematologic cancer	6.27e-06	0.000186	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IL2—hematologic cancer	6.26e-06	0.000185	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CDKN1B—hematologic cancer	6.26e-06	0.000185	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—IL6—hematologic cancer	6.23e-06	0.000184	CbGpPWpGaD
Metipranolol—ADRB2—GPCR downstream signaling—AKT1—hematologic cancer	6.19e-06	0.000183	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CASP3—hematologic cancer	6.14e-06	0.000182	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IL2—hematologic cancer	6.13e-06	0.000181	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CCND1—hematologic cancer	6.11e-06	0.000181	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—IL6—hematologic cancer	6.1e-06	0.00018	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—JUN—hematologic cancer	6.09e-06	0.00018	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CCND1—hematologic cancer	5.97e-06	0.000177	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—JUN—hematologic cancer	5.96e-06	0.000176	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—CDKN1A—hematologic cancer	5.91e-06	0.000175	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PTEN—hematologic cancer	5.89e-06	0.000174	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—CDKN1A—hematologic cancer	5.78e-06	0.000171	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MAPK8—hematologic cancer	5.77e-06	0.000171	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PTEN—hematologic cancer	5.77e-06	0.000171	CbGpPWpGaD
Metipranolol—ADRB1—Signaling by GPCR—AKT1—hematologic cancer	5.75e-06	0.00017	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MAPK8—hematologic cancer	5.64e-06	0.000167	CbGpPWpGaD
Metipranolol—ADRB2—Signaling by GPCR—AKT1—hematologic cancer	5.62e-06	0.000166	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—EP300—hematologic cancer	5.62e-06	0.000166	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—EP300—hematologic cancer	5.5e-06	0.000163	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—SRC—hematologic cancer	5.47e-06	0.000162	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—SRC—hematologic cancer	5.35e-06	0.000158	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—VEGFA—hematologic cancer	5.32e-06	0.000158	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—STAT3—hematologic cancer	5.27e-06	0.000156	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—NRAS—hematologic cancer	5.26e-06	0.000156	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—VEGFA—hematologic cancer	5.21e-06	0.000154	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—STAT3—hematologic cancer	5.16e-06	0.000153	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—NRAS—hematologic cancer	5.14e-06	0.000152	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MAPK3—hematologic cancer	5.04e-06	0.000149	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MAPK3—hematologic cancer	4.93e-06	0.000146	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—MYC—hematologic cancer	4.9e-06	0.000145	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TGFB1—hematologic cancer	4.89e-06	0.000145	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—MYC—hematologic cancer	4.79e-06	0.000142	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TGFB1—hematologic cancer	4.78e-06	0.000141	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—KRAS—hematologic cancer	4.53e-06	0.000134	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—KRAS—hematologic cancer	4.43e-06	0.000131	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—PIK3CA—hematologic cancer	4.16e-06	0.000123	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—PIK3CA—hematologic cancer	4.07e-06	0.00012	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—TP53—hematologic cancer	4.02e-06	0.000119	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—TP53—hematologic cancer	3.93e-06	0.000116	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—HRAS—hematologic cancer	3.85e-06	0.000114	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—HRAS—hematologic cancer	3.76e-06	0.000111	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—IL6—hematologic cancer	3.68e-06	0.000109	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—IL6—hematologic cancer	3.6e-06	0.000107	CbGpPWpGaD
Metipranolol—ADRB1—Signaling Pathways—AKT1—hematologic cancer	3.4e-06	0.000101	CbGpPWpGaD
Metipranolol—ADRB2—Signaling Pathways—AKT1—hematologic cancer	3.32e-06	9.83e-05	CbGpPWpGaD
